Activity OverviewFrontline providers need targeted education on the initial presentation, manifestations, and demographics of lupus to identify, diagnose, and refer patients with suspected lupus more effectively. The seven activities in this series can increase your awareness, knowledge, and self-efficacy regarding the diagnosis, referral, treatment, and possible co-management of a lupus patient.Lupus Virtual Provider Education SeriesThis activity is part of a series. See the other activities in the series below.Lupus Virtual Provider Education Series: All ActivitiesLupus Virtual Provider Education Series Activity 1: Lupus IntroductionLupus Virtual Provider Education Series Activity 2: Laboratory Testing in LupusLupus Virtual Provider Education Series Activity 3: Medications in LupusLupus Virtual Provider Education Series Activity 4: Lupus FlaresLupus Virtual Provider Education Series Activity 5: Lupus NephritisLupus Virtual Provider Education Series Activity 6: Pregnancy and LupusLupus Virtual Provider Education Series Activity 7: Health Maintenance and Preventive Care Considerations in LupusRegistration is complimentary.Target AudiencePrimary care providers, physician assistants, advanced practice nurses.Learning ObjectivesUpon completion of this activity, participants should be able to:Activity 1: Lupus IntroductionIdentify the demographics of lupus and highest-risk populations for lupus complications​Identify classic and atypical presentations of SLE​Discuss the differential diagnosis of patients presenting with symptoms that may suggest SLE​Identify high-yield lupus-specific symptoms Activity 2: Laboratory Testing in LupusRecognize the autoimmune serologic associations of SLE​Identify when to order lab tests to evaluate SLE Activity 3: Medications in LupusIdentify the different categories of drugs used in managing lupus​Recognize the different components of the EULAR 2023 Guidelines and its application in lupus management ​Determine the severity of lupus disease activity and how this influences treatment protocols ​Recognize the importance of hydroxychloroquine in the lupus management armamentarium Identify medications are used for different clinical manifestations of lupus, using different case study scenariosIdentify that non-pharmacological interventions are important along with medications for lupus management Activity 4: Lupus FlaresRecognize symptoms and signs that may indicate a lupus flare​Identify high acuity signs and symptoms that may warrant hospital admission Activity 5: Lupus NephritisDescribe the epidemiology of lupus nephritis ​Recognize how to diagnose lupus nephritis​Discuss the pathology in lupus nephritis​Recognize when to refer to nephrology​Describe treatment paradigms for lupus nephritis Activity 6: Pregnancy and LupusIdentify important considerations for fertility and family planning in patients with lupus including medications and lupus activity​Discuss the implication of antiphospholipid antibodies in pregnancy​Discuss the role of SSA/SSB antibodies in pregnancy and neonatal lupus Activity 7: Health Maintenance and Preventive Care Considerations in LupusIdentify the risk factors for premature coronary artery disease in lupus patients and risk modification strategies​Recognize osteoporosis risk factors and various treatment considerations in women of childbearing age​Identify appropriate immunization schedules for lupus patients and understand contraindications to immunization among patients on immunosuppressive medicationsCE & MOC InformationCMEACCME Accreditation StatementThe American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.See the ACR's CME Mission Statement. For more information, download the AMA PRA Booklet.AMA Designation StatementThe American College of Rheumatology designates this Enduring Material for a maximum of 7.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.CME credit must be claimed by March 30, 2028, at 11:59 PM ET.MOCMOC Recognition Statement: American Board of Internal Medicine (ABIM)Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7.00 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board. After submitting a reflective statement with key takeaways from the activity, MOC points will be applied for ABIM diplomates to the ABIM diplomate number and date of birth provided when you registered. Points are sent nightly to ACCME and then transferred to the ABIM Physician Portal. Please allow at least 48 hours for points to display in the portal.MOC points must be claimed by March 30, 2028, at 11:59 PM ET.Financial Relationship DisclosuresACR Disclosure StatementIt is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.Nature of Financial RelationshipsAll individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:Advisor or review panel memberConsultantEmployeeOfficer or Board MemberGrant/research supportSpeaker/honoraria includes speaker’s bureau, symposia, and expert witnessIndependent contractorExecutive role and/or ownership interestRoyalties and/or patent beneficiaryIntellectual property/patentsStock options or bond holdings in a for-profit corporation or self-directed pension planPrivate investigatorExpert witnessEquity interestOther: specify detailsNone: Has no relevant financial relationship(s) with ineligible companies to disclose.All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated.Tanmayee Bichile, MD (Planner) – GSK1Parastoo Fazeli, MD (Planner) – Amgen6, AstraZeneca1, Janssen1, Novartis1Nilasha Ghosh, MD, MS, RhMSUS (Planner) – GoodRx2, Musculo2Schartess Culpepper Pace, MD (Planner) – NoneNina Ramessar, MBBS (Planner) – GSK6, AstraZeneca6, AbbVie2Supraja Yeturi, MBBS (Planner) – NoneKimberly DeQuattro, MD, MM (Reviewer) – NoneElizabeth Frame, MD (Reviewer) – NoneLauren Smith, MD (Reviewer) – BMS Foundation5Acknowledgement of Commercial SupportThis activity is supported by the Centers for Disease Control and Prevention (CDC) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award of $7 million with 100 percent funded by CDC/HHS. The activity content was provided by the author(s) and does not necessarily represent the official views of, nor an endorsement by, the CDC/HHS or U.S. Government.Educational PoliciesSee ACR educational activity policies, including the online enduring activity refund policy.

Activity OverviewFrontline providers need targeted education on the initial presentation, manifestations, and demographics of lupus to identify, diagnose, and refer patients with suspected lupus more effectively. This introduction to lupus can increase your awareness, knowledge, and self-efficacy regarding the diagnosis, referral, treatment, and possible co-management of a lupus patient. Lupus Virtual Provider Education SeriesThis activity is part of a series. See the other activities in the series below.Lupus Virtual Provider Education Series: All ActivitiesLupus Virtual Provider Education Series Activity 2: Laboratory Testing in LupusLupus Virtual Provider Education Series Activity 3: Medications in LupusLupus Virtual Provider Education Series Activity 4: Lupus FlaresLupus Virtual Provider Education Series Activity 5: Lupus NephritisLupus Virtual Provider Education Series Activity 6: Pregnancy and LupusLupus Virtual Provider Education Series Activity 7: Health Maintenance and Preventive Care Considerations in Lupus Registration is complimentary.Target AudiencePrimary care providers, physician assistants, advanced practice nurses.Learning ObjectivesUpon completion of this activity, participants should be able to:Identify the demographics of lupus and highest-risk populations for lupus complications​Identify classic and atypical presentations of SLE​Discuss the differential diagnosis of patients presenting with symptoms that may suggest SLE​Identify high-yield lupus-specific symptomsCE & MOC InformationCMEACCME Accreditation StatementThe American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. See the ACR's CME Mission Statement. For more information, download the AMA PRA Booklet.AMA Designation StatementThe American College of Rheumatology designates this Enduring Material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. CME credit must be claimed by March 30, 2028, at 11:59 PM ET.MOCMOC Recognition Statement: American Board of Internal Medicine (ABIM) Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board.  After submitting a reflective statement with key takeaways from the activity, MOC points will be applied for ABIM diplomates to the ABIM diplomate number and date of birth provided when you registered. Points are sent nightly to ACCME and then transferred to the ABIM Physician Portal. Please allow at least 48 hours for points to display in the portal. MOC points must be claimed by March 30, 2028, at 11:59 PM ET.Financial Relationship DisclosuresACR Disclosure StatementIt is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.Nature of Financial RelationshipsAll individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:Advisor or review panel memberConsultantEmployeeOfficer or Board MemberGrant/research supportSpeaker/honoraria includes speaker’s bureau, symposia, and expert witnessIndependent contractorExecutive role and/or ownership interestRoyalties and/or patent beneficiaryIntellectual property/patentsStock options or bond holdings in a for-profit corporation or self-directed pension planPrivate investigatorExpert witnessEquity interestOther: specify detailsNone: Has no relevant financial relationship(s) with ineligible companies to disclose. All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated. Tanmayee Bichile, MD (Planner) – GSK1Parastoo Fazeli, MD (Planner) – Amgen6, AstraZeneca1, Janssen1, Novartis1Nilasha Ghosh, MD, MS, RhMSUS (Planner) – GoodRx2, Musculo2Schartess Culpepper Pace, MD (Planner) – NoneNina Ramessar, MBBS (Planner) – GSK6, AstraZeneca6, AbbVie2Supraja Yeturi, MBBS (Planner) – NoneKimberly DeQuattro, MD, MM (Reviewer) – NoneElizabeth Frame, MD (Reviewer) – NoneLauren Smith, MD (Reviewer) – BMS Foundation5Acknowledgement of Commercial SupportThis activity is supported by the Centers for Disease Control and Prevention (CDC) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award of $7 million with 100 percent funded by CDC/HHS. The activity content was provided by the author(s) and does not necessarily represent the official views of, nor an endorsement by, the CDC/HHS or U.S. Government.Educational Activity PoliciesSee ACR educational activity policies, including the online enduring activity refund policy.

Activity OverviewRheum2Learn 2.0 is case-based fundamental clinical rheumatology education for residents. Each interactive activity includes three patient cases that focus on the care and assessment of individuals with rheumatologic diseases. The included activities use interactive patient cases to simulate clinical scenarios commonly encountered in primary care, inpatient, and critical care settings. Learners are guided to recognize disease patterns, build differential diagnoses, select appropriate tests, and develop treatment strategies in collaboration with rheumatology specialists. Key topics span rheumatoid arthritis, lupus, crystalline arthritis, osteoarthritis, myopathies, systemic sclerosis, pediatric rheumatology, infectious arthritis, osteoporosis, and vasculitis. See below for a complete list of the 15 included activities.Rheum2Learn SeriesThis activity is part of a series. See the other activities in the series below.Rheum2Learn 2.0: Crystalline ArthritisRheum2Learn 2.0: Infectious ArthritisRheum2Learn 2.0: Inflammatory MyopathiesRheum2Learn 2.0: Musculoskeletal DisordersRheum2Learn 2.0: Musculoskeletal ExaminationRheum2Learn 2.0: OsteoporosisRheum2Learn 2.0: OsteoarthritisRheum2Learn 2.0: Pediatric RheumatologyRheum2Learn 2.0: Rheumatic Manifestations of Systemic DiseaseRheum2Learn 2.0: Rheumatoid ArthritisRheum2Learn 2.0: Sjögren’s DiseaseRheum2Learn 2.0: SpondyloarthritisRheum2Learn 2.0: Systemic Lupus ErythematosusRheum2Learn 2.0: Systemic SclerosisRheum2Learn 2.0: Systemic VasculitisRegistration is complimentary.Target AudienceResidents in training who may provide care for patients with rheumatic diagnoses in primary care, inpatient, critical care, and other clinical contexts.The activity may also be of interest to medical students, fellows in training, advanced practice providers, practicing physicians, and other health care professionals who seek to strengthen their clinical knowledge of rheumatic diseases.Learning ObjectivesUpon completion of this activity, participants should be able to:Recognize disease patterns using clinical data and patient history.Formulate a comprehensive differential diagnosis based on disease patterns and diagnostic clues.Select appropriate diagnostic tests and labs to narrow down the diagnosis.Develop treatment strategies in collaboration with rheumatology specialists.See individual activities (linked above) for activity-specific learning objectives. CE & MOC InformationThis activity is not eligible for CME/MOC.Acknowledgement of Commercial SupportRheum2Learn 2.0: Inflammatory Myopathies, Rheum2Learn 2.0: Systemic Lupus Erythematosus, Rheum2Learn 2.0: Pediatric Rheumatology, Rheum2Learn 2.0: Rheumatic Manifestations of Systemic Disease, Rheum2Learn 2.0: Sjögren’s DiseaseThese projects were supported by grant number 1 NU58DP006908-01-00 – Component A: Developing and Disseminating Programs to Build Sustainable Lupus Awareness, Knowledge, Skills and Partnerships. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Department of Health and Human Services, Centers for Disease Control and Prevention.Educational Activity PoliciesSee ACR educational activity policies, including the online enduring activity refund policy.

Activity OverviewThe Advanced Rheumatology Course is a 19-activity series for advanced practice providers and other professionals who need a deeper dive into rheumatology.  The series covers how to assess and manage patients with rheumatic disease, develop strategies to integrate NP/PAs into rheumatology practice, and improve access to care for patients. The advanced information will help experienced practice providers function well in rheumatology and foster inter-professional collaboration. In this activity, you will explore the necessary knowledge and skills to effectively evaluate, treat, and educate pediatric connective tissue disease patients and their families.Advanced Rheumatology Course SeriesThis activity is part of a series. See the other activities in the series below.Advanced Rheumatology Course: All ActivitiesARC01: Musculoskeletal Structure And Function And Inflammation And ImmunityARC02: Framework for Clinical Decision Making in RheumatologyARC03: Laboratory Evaluation of Rheumatic DiseaseARC04: Imaging of ArthritisARC05: Coding and Practice IssuesARC06: Therapeutic Interventions And ResourcesARC07: OsteoarthritisARC08: RA and Seronegative Inflammatory ArthropathiesARC09: Systemic Lupus ErythematosusARC010: Systemic Inflammatory Conditions: Inflammatory MyopathyARC11: Vasculitis, Arteritis and PMRARC12: Crystal-Induced ArthropathiesARC13: Pain SyndromesARC14: SpondyloarthritisARC15: Infection-Related ArthritisARC16: Osteoporosis And Other Metabolic Bone DisordersARC17: Comprehensive Overview of Juvenile Idiopathic Arthritis (JIA)ARC18:Comprehensive Overview of Pediatric Connective Tissue Diseases (CTD)ARC19: Pediatric Noninflammatory Musculoskeletal PainRegistration is discounted for ACR/ARP members. If you are not a member, consider joining ACR/ARP.Target AudienceAdvanced practice nurses and physician assistants. Fellows-in training, residents, students, primary care providers, physical therapists, and researchers may also benefit.Learning ObjectivesUpon completion of this activity, participants should be able to: Identify the three most common connective tissue diseases (CTDs) in children: systemic lupus erythematosus, juvenile dermatomyositis and sclerodermaRecognize the epidemiology and pathogenesis, clinical features, differential diagnosis, clinical course and prognosis for these three CTDsComplete a comprehensive evaluation for each of these three CTDsDesign a management plan for each of these three CTDsCE & MOC InformationACCME Accreditation StatementThe American College of Rheumatology (ACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.AMA Designation StatementThe American College of Rheumatology designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.See the ACR's CME Mission Statement. For more information, download the AMA PRA Booklet.CME credit must be claimed by August 14, 2026, at 11:59 PM ET.Financial Relationship DisclosuresACR Disclosure StatementIt is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners' and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.Nature of Financial RelationshipsAll individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to: Advisor or review panel memberConsultantEmployeeOfficer or Board MemberGrant/research supportSpeaker/honoraria includes speaker’s bureau, symposia, and expert witnessIndependent contractorExecutive role and/or ownership interestRoyalties and/or patent beneficiaryIntellectual property/patentsStock options or bond holdings in a for-profit corporation or self-directed pension planPrivate investigatorExpert witnessEquity interestOther: specify detailsNone: Has no relevant financial relationship(s) with ineligible companies to disclose.All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated.AuthorsHeather Benham, DNP, APRN, CPNP-PC, RhMSUS – No relevant financial relationships to discloseEditors and ReviewersNatasha Ruth, MD, MS – No relevant financial relationships to discloseMarcy Bolster, MD – AbbVie2; American Board of Internal Medicine: Chair, ABIM Rheumatology Board6; Amgen2; Corbus Pharmaceuticals2; Cumberland2; Genentech2; Gilead Sciences5; Johnson & Johnson1; Pfizer2Julie Lahti – No relevant financial relationships to discloseAcknowledgement of Commercial SupportThe project was supported by Grant number 1 NU58DP006908-03-00 – Component A; Developing and Disseminating Programs to Build Sustainable Lupus Awareness, Knowledge, Skills and Partnerships. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Department of Health and Human Services, Centers for Disease Control and Prevention.Educational Activity PoliciesSee ACR educational activity policies, including the online enduring activity refund policy.